KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer

Charles S. Fuchs, Toshihiko Doi, Raymond Woo-Jun Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia Ibrahim Jalal, Manish A. Shah, Jean-Philippe Metges, Marcelo Garrido, Talia Golan, Mario Mandala, Zev A. Wainberg, Daniel V.T. Catenacci, Yung-Jue Bang, Jiangdian Wang, Minori Koshiji, Rita P. Dalal, Harry H. Yoon

Yale Cancer Center, New Haven, CT
National Cancer Center Hospital East, Chiba, Japan
Princess Margaret Cancer Centre, Toronto, ON, Canada
Aichi Cancer Center Hospital, Aichi, Japan
Osaka University Graduate School of Medicine, Osaka, Japan
Portuguese Institute of Oncology Libon, Porto, Portugal
University of Pittsburgh Medical Center, Pittsburgh, PA
Indiana University School of Medicine, Indianapolis, IN
Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY
Centre Hospitalier Regional Universitaire (CHRU) de Brest - Hopital Morvan, Brest, France
Pontificia Universidad Católica de Chile, Santiago, Chile
Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel
ASST Papa Giovanni XXIII, Cancer Center, Bergamo, Italy
Ronald Reagan UCLA Medical Center, Los Angeles, CA
University of Chicago Pritzker School of Medicine, Chicago, IL
Seoul National University Hospital, Seoul, Republic of Korea
Merck & Co., Inc., Kenilworth, NJ
Mayo Clinic, Rochester, MN